evenfolio

Chemicals · NSE: AARTIIND

Aarti Industries

Price as of 12 Nov 2026
483.90+0.13%

Q2 FY27 earnings call · Guided by management

Call held 2 Nov 2026 · Read the filing on NSEFiling

20–25​productsZone IV product launches · Zone IV · FY27-FY28Kotecha · p. 5
30–40​%Energy share of portfolio · Energy · midtermKotecha · Q&A · p. 20
15–20​%Tax rate · FY27 or FY28Gandhi · Q&A · p. 18
₹700–800​CrCapex · FY27Kotecha · p. 4
M.Cap
₹17,552Cr
P/E
29.6×
1Y return
+21.86%
From 52W high
−12.3%

Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.

Share price

Results Q2 FY27, as filed · consolidated · ₹ Cr

Q2 FY27Q2 FY26YoYQ1 FY27QoQ
Revenue3,6682,100+74.7%2,387+53.7%
EBITDA411291+41.0%382+7.5%
EBITDA margin11.2%13.9%-268 bps16.0%-481 bps
One-off items—22—2—
PBTProfit before tax20494+118.6%180+13.5%
Net profit168106+58.8%155+8.6%
EPS (₹)4.652.91+59.8%4.26+9.2%

From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures. In Q1 FY27 the filing tags the owners' profit as ₹0 Cr against its own period profit; the period profit less minority interest is shown.

Guidance

Capex · FY27Rs 700-800 CrFY27 capex planned at Rs 700 crore to Rs 800 crore
Capex · FY2925 US$ millionDedicated facility for new contract, capex under US$25 million, operations targeted FY29

Guidance for next year to be given closer to the end of the financial year

Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 7
“But broadly, we expect the current momentum to continue and on the basis of that, we will come up with appropriate guidance for the next year, closer to the end of the financial year.”

Zone IV: Aim for Zone IV to add to EBITDA in FY28

Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 10
“The aspiration is to get Zone IV additive to EBITDA in FY28 itself and that is the current plan.”

Management says three levers give line of sight to its guided EBITDA range

Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 19
“So across the three levers is what gives us line of sight to achieve the range that we had mentioned in our guidance.”

More figures from the call

Zone IV · Guidance
₹250–350​CrZone IV bottom line · first 18 months
“From a margin standpoint, in the first 18 months, our target is to achieve INR250 crore to INR350-odd crore of bottom line from Zone IV, and I think we continue to push for that aspiration.”
Suyog Kotecha · Managing Director and Chief Executive Officer · Q&Ap. 9
Fuel Additives · Capacity
360​KTPACapacity · first quarter of 2026
“In Fuel Additives, the capacity utilization remained strong in Q2 following our expansion from 290 KTPA to 360 KTPA in the first quarter of 2026.”
Suyog Kotecha · Managing Director and Chief Executive Officerp. 4
DCB · Capacity
140​KTPACapacity
“For DCB, the capacity debottlenecking to 140 KTPA remains aligned with downstream PDCB demand.”
Suyog Kotecha · Managing Director and Chief Executive Officerp. 4
Augene Chemicals JV · Acquisitions and new business
₹300–400​CrSteady-state revenue · steady state
“Commercial production is expected to commence soon, with steady-state revenue projected at Rs. 300-400 crore.”
Suyog Kotecha · Managing Director and Chief Executive Officerp. 5
Company · Order book
25–30​%Share of business from long-term partnerships
“Usually, it is around 25% to 30% of our business that comes through some of these long-term partnerships. We hope the share of that will go up going forward as we do more and more such partnerships.”
Suyog Kotecha · Managing Director and Chief Executive Officer · Q&Ap. 16
Company · Margins and costs
50–60​initiativesCost optimisation initiatives
“We have a pipeline of 50 to 60 different initiatives, typically focused on yield, energy, throughput quality, all four levers and including fixed cost optimization.”
Suyog Kotecha · Managing Director and Chief Executive Officer · Q&Ap. 19

In short

  1. 01Q2 FY27 revenue was Rs 3,887 crore, up 73%; EBITDA was Rs 418 crore, up 44%.
  2. 02Net debt rose to over Rs 4,650 crore on higher raw material prices; up to Rs 1,000 crore fund raise approved to deleverage.
  3. 03Management says it has line of sight to its FY28 EBITDA guidance range; next year's guidance to come near year end.
  4. 04Zone IV Phase I commissioned on 7 September 2026; remaining chemistry blocks expected within FY27, ramp-up through FY28.
  5. 05Zone IV targeted at Rs 250-350 crore bottom line in first 18 months and to add to EBITDA in FY28.
  6. 06New 10+ year supply contract signed with revenue potential of about Rs 1,500 crore; operations targeted for FY29.
  7. 07FY27 capex planned at Rs 700-800 crore; NCB expansion would be debottlenecking, not greenfield.
  8. 08Energy expected to settle at 30% to 40% of the portfolio in the midterm.

Capex

Zone IV: Zone IV Phase I commissioned on September 7, 2026

Suyog Kotecha · Managing Director and Chief Executive Officer · p. 5
“The Phase I of Zone IV was officially commissioned on September 7, 2026.”

Zone IV: Calcium Chloride, PEDA and part of multipurpose plant operational, under stabilisation

Suyog Kotecha · Managing Director and Chief Executive Officer · p. 5
“The Calcium Chloride unit, the PEDA (2-Phenyl Ethyl Diethyl Aniline) plant, and a section of the Multipurpose Plant (MPP) are now operational and are undergoing stabilization.”

Zone IV: Remaining 4 Zone IV chemistry blocks expected online within this financial year

Suyog Kotecha · Managing Director and Chief Executive Officer · p. 5
“The remaining 4 chemistry blocks are expected to come online within this financial year, positioning Zone IV as a strategic growth driver for next 18-24 months.”

Zone IV: Most CWIP should be capitalised by 31 March 2027

Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 9
“So by 31st March 2027, most of it should get capitalized.”

NCB: NCB expansion to be debottlenecking, not greenfield; capital intensity not much higher

Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 13
“Even in NCB, we are looking at a debottlenecking capex and not necessarily a greenfield capex. So from that point of view, capital intensity would not be significantly higher”

Capacity

NCB: NCB utilisation elevated; capacity expansion under evaluation

Suyog Kotecha · Managing Director and Chief Executive Officer · p. 4
“With current NCB asset utilization remaining elevated, the capacity expansion initiatives are under evaluation by the management team.”

MMA: MMA ran at almost full capacity in Q2

Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 9
“I think in the second quarter, we ran almost at full capacity.”

Zone IV: Calcium Chloride plant above design capacity within three months

Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 10
“The Calcium Chloride plant that we commissioned has achieved more than design capacity within first three months of operation.”

Zone IV: PEDA plant reached design capacity within two months

Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 10
“The PEDA plant that we commissioned is able to achieve its design capacity and design norms within the first two months of its operation.”

Energy: Energy: near-term aim is to stabilise at current capacity before weighing expansion

Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 19
“So for the time being, our objective is to stabilize at this capacity and as I mentioned earlier, stabilize our integrated value chain presence, which brings more robustness, more stability to the earnings profile of these value chains. Once we have achieved that, then we could go back and potentially evaluate further expansion.”

Order book

10+ year supply agreement with global specialty chemical major, revenue potential ~Rs 1,500 crore

Suyog Kotecha · Managing Director and Chief Executive Officer · p. 5
“On October 13, 2026, we also entered into a dedicated 10+ year manufacturing and supply agreement with a global specialty chemical major, representing a revenue potential of ~Rs. 1,500 crore.”

Two specialty contracts run to late 2030s-2040; AgChem contract to 2029-2030

Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 6
“I think if I am not wrong, we are expecting this to run in late 2030s up to 2040, some of them versus the AgChem contract will last till 2029, 2030 kind of a time frame.”

Specialty chemicals: Specialty contracts structured around margins; performing as per expectations

Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 6
“But given the nature of our commercial arrangement, what is more important is the bottom line because the commercials are structured around margins and not necessarily around top line and that continues to perform as per expectations.”

Specialty chemicals: Advanced polymer demand for EVs and electronics picked up; contract volumes up

Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 6
“The demand portfolio for the advanced polymer going into EVs and electronics’ space has actually picked up. So the volumes there have gone up.”

No discontinuation expected from the three long-term contracts

Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 6
“So there is no reason that we expect discontinuation of business performance from any of these contracts.”

Segments

Agrochemicals: Agrochemicals second half may reflect weaker domestic monsoon

Suyog Kotecha · Managing Director and Chief Executive Officer · p. 3
“The second half might reflect the impact of weaker monsoon in the domestic market.”

Polymers & Additives: PDA softness dragged Q2; traction expected to resume in Q3 FY27 on DCB demand

Suyog Kotecha · Managing Director and Chief Executive Officer · p. 3
“While softness in the PDA chain created a short-term drag on our Q2 FY27 performance, we expect traction to resume in Q3 FY27, underpinned by accelerating DCB demand.”

PDA: Re-evaluating use of PDA assets; no volume growth pursued there for now

Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 6
“PDA is one chain where we are reevaluating how we should utilize those assets in the most efficient manner. But there, at this point in time, we are not pursuing strategic growth from a volume standpoint”

Ethylation: Ethylation volume growth expected to continue

Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 6
“with our multiproduct strategy, including MEA, DEA and some of the other specialty ethylation/propylation-based chemistries, we expect the volume growth to continue there as well.”

Pharma: Pharma volumes grew significantly; NCB chain expansion being considered

Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 8
“I think that is one sector where we have also significantly grown in terms of volumes, which is reflected in our NCB chain utilization levels and we are also considering potential expansion possibilities for that value chain.”

Demand

NCB: NCB demand very strong; capacity expansion considered on customer requests

Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 6
“The NCB, which is predominantly a domestic market, the demand trends are very strong. We are actually considering capacity expansion being pushed by requests from our customers.”

DCB: DCB first half usually softer, second half strong as US flows start

Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 6
“On DCB side, the first half is usually a softer, second half is very strong as the U.S. flows kick in.”

Energy: Energy pull-up in Q2 linked to strong refining margins and gasoline-naphtha cracks

Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 7
“We have seen a huge pull-up from the energy portfolio in the second quarter specifically, which was linked to extremely strong refining margin and gasoline- naphtha cracks.”

Energy: Domestic demand for Fuel Additives picking up

Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 10
“Second, we have domestic demand picking up for the Fuel Additives portfolio in the market and in some cases, some of the exported volume has also been bought in the domestic market.”

Energy: Gasoline-naphtha crack was $20-plus per barrel last quarter

Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 11
“The gasoline-naphtha crack, it was very robust. It was $20-plus per barrel, if I look at last quarter.”

Margins and costs

Almost all raw materials rose in price; Sulphur up over 5-6x

Suyog Kotecha · Managing Director and Chief Executive Officer · p. 3
“Almost all of our raw materials saw significant price increase, while RMs such as Sulphur saw prices surge by over 5-6x”

Pharma & Fluoro Products: Fluoro products margins remain under pressure

Suyog Kotecha · Managing Director and Chief Executive Officer · p. 3
“The Fluoro products’ margins continue to remain under pressure.”

NCB: NCB spreads above original assumption, offset by Zone IV delay

Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 7
“So there is definitely an upside in the NCB chain that we are seeing compared to our assumption. At the same time, we are running a bit delayed on Zone IV, right.”

Possible margin upside if China anti-involution and VAT rebate removal spread

Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 7
“If there is a further improvement in margin spread due to China's current stand linked to anti-involution and removal of, VAT rebate removal if that sort of gets passed on to multiple other value chains, we could see an upside in the margins”

Agrochemicals: Agrochemical quarterly contracts pass through prices with a one-quarter lag

Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 7
“In many of the segments, for example, in Agrochemicals, we have quarterly contracts, right. So there is a lag of quarter when it comes to pass-through of the pricing.”

Debt and working capital

Net debt rose to over Rs 4,650 crore as raw material prices stretched working capital

Suyog Kotecha · Managing Director and Chief Executive Officer · p. 4
“Elevated RM prices have also stretched our working capital requirements over the past two quarters, pushing our net debt to over Rs. 4,650 crore and leading to higher finance costs.”

Working capital optimised to 55 to 60 days

Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 8
“But in terms of days, we have practically optimized to 55 to 60 days of working capital, which is the optimum level at which we could operate.”

Rs 800 crore to Rs 1,000 crore of inventory on the water at any time

Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 10
“we roughly have anywhere between INR 800 crore to INR 1,000 crore worth of inventory on the waters”

Fund raising

Board approved enabling resolution to raise up to Rs 1,000 crore

Suyog Kotecha · Managing Director and Chief Executive Officer · p. 4
“the Board, on October 1, 2026, approved an enabling resolution to raise up to Rs. 1,000 crore”

Shareholders approved the fund raise resolution at EGM on 31 October 2026

Suyog Kotecha · Managing Director and Chief Executive Officer · p. 4
“The said enabling resolution has been approved by the Shareholders in the EGM held on 31st October 2026”

Acquisitions and new business

Energy: Several new energy solutions expected to launch over next 12 to 24 months

Suyog Kotecha · Managing Director and Chief Executive Officer · p. 3
“Leveraging our bulk shipment capabilities and robust R&D pipeline, we anticipate launching of several new solutions over the next 12 to 24 months.”

Aarti Circularity: Aarti Circularity plastic recycling JV execution on track

Suyog Kotecha · Managing Director and Chief Executive Officer · p. 5
“Project execution for Aarti Circularity (Plastic Recycling JV) remains on track.”

Evaluating customer-backed projects in personal care, flavours, batteries, defence

Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 15
“Right now, as we speak, we are looking at strategic projects backed up by customers' demand in areas like personal care, for example, flavors and fragrances, batteries, in defense.”

New contract a start; more projects and capacity expansion hoped with client

Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 16
“I think this is just a start of relationship with a new client. We hope to do many more projects, including expanding capacity under the existing contracts”

Only signed deals announced; other application partnerships still in talks

Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 18
“As of now, whatever has got confirmed and signed is what we have communicated to the market and rest of them remains in the conversation stage.”

One-offs

Q1 inventory and FX gain was about Rs 50-60 crore; nothing significant in Q2

Chetan Gandhi · Chief Financial Officer · Q&A · p. 8
“In first quarter, we had indicated that the inventory and FX was roughly around INR 50 - 60 crore as a combined number.”

Provision taken in the quarter is for goods in transit

Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 16
“Yes, it is for goods in transit.”

Risks

Q3 domestic raw material availability good; imported raw materials may see supply gaps

Suyog Kotecha · Managing Director and Chief Executive Officer · p. 4
“early indications for Q3 point indicates for the domestic RM, we will continue to have good availability and visibility while for imported RM, there could be supply chain gaps that we will have to mitigate.”

Zone IV fixed costs from Q4 and a crude price correction named as risks

Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 7
“There might be certain issues around Zone IV commissioning and the fixed cost associated with that coming into the P&L around Q4 and if there is a major correction in the global crude oil pricing scenario and if that has an impact potentially on some of the inventory, these are the two issues that we have to watch out for.”

Inventory loss risk managed by forward booking, cannot be fully eliminated

Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 8
“Wherever possible, we are trying to do forward booking of the contracts to ensure that our exposure gets minimized to the best extent possible. But irrespective of everything that we do, the risk cannot be fully eliminated.”

PDA: PDA hit by Chinese overcapacity and dumping

Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 11
“No, we see huge overcapacity and dumping by some of the Chinese players for this particular product in the global market.”

MMA: MMA competitors have added capacity; company still placing its volumes

Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 14
“Competition is there and some of them have ramped up the capacity. We have also ramped up our capacity. But we have also been able to place our capacity despite increasing competition.”

Other

Quarterly EBITDA crossed Rs 400 crore, reaching a record Rs 418 crore

Suyog Kotecha · Managing Director and Chief Executive Officer · p. 2
“Most notably, our quarterly EBITDA surpassed the Rs. 400-crore threshold, reaching a record of Rs. 418 crore.”

Q2 FY27 revenue Rs 3,887 crore, up 73% year on year

Suyog Kotecha · Managing Director and Chief Executive Officer · p. 4
“Revenues in Q2 FY27 were at Rs. 3,887 crore, an increase of 73% over Q2 of last year.”

Q2 FY27 EBITDA up 44% year on year to Rs 418 crore

Suyog Kotecha · Managing Director and Chief Executive Officer · p. 4
“Q2 FY27 EBITDA increased by 44% year-on-year reaching Rs. 418 crore.”

Q2 FY27 PAT Rs 169 crore, up about 60% year on year

Suyog Kotecha · Managing Director and Chief Executive Officer · p. 4
“PAT for the quarter increased to Rs. 169 crore with growth of about 60% over the same quarter in the previous year.”

Over 50 GenAI use cases executed last quarter

Suyog Kotecha · Managing Director and Chief Executive Officer · p. 4
“our successful execution of over 50 GenAI use cases across our workspace last quarter alone.”

Sources

Management's own statements, quoted from its NSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.

Search

Search funds, ETFs, stocks, pages and tools